Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With METamp After Osimertinib First-Line Treatment

被引：0
|
作者：
Corassa, Marcelo [1 ]
Abreu, Rodrigo Fonseca [2 ]
Cordeiro de Lima, Vladmir Claudio [1 ]
Torrezan, Giovana Tardim [3 ,4 ]
Cavalher, Felicia Peterson [1 ]
Silva, Tullio Novaes [2 ]
de Oliveira, Thiago Bueno [1 ]
Freitas, Helano Carioca [1 ]
Carraro, Dirce Maria [3 ,4 ]
Costa, Felipe D'Almeida [2 ]
机构：
[1] AC Camargo Canc Ctr, Dept Med Oncol, R Prof Antonio Prudente, Sao Paulo, Brazil
[2] Dept Pathol, R Prof Antonio Prudente, Sao Paulo, Brazil
[3] AC Camargo Canc Ctr, Genom & Mol Biol Grp, Int Res Center CIPE, Sao Paulo, Brazil
[4] Natl Inst Sci & Technol Oncogen INCITO, Sao Paulo, Brazil
来源：
JCO PRECISION ONCOLOGY | 2022年 / 6卷
关键词：
SQUAMOUS-CELL CARCINOMA; HISTOLOGIC TRANSFORMATION; KINASE INHIBITORS; FREQUENCY; CANCER;
D O I：
10.1200/PO.22.00367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [41] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [42] Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
    Adua, Sally J.
    Arnal-Estape, Anna
    Zhao, Minghui
    Qi, Bowen
    Liu, Zongzhi Z.
    Kravitz, Carolyn
    Hulme, Heather
    Strittmatter, Nicole
    Lopez-Giraldez, Francesc
    Chande, Sampada
    Albert, Alexandra E.
    Melnick, Mary-Ann
    Hu, Bomiao
    Politi, Katerina
    Chiang, Veronica
    Colclough, Nicola
    Goodwin, Richard J. A.
    Cross, Darren
    Smith, Paul
    Nguyen, Don X.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [43] Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer
    Sally J. Adua
    Anna Arnal-Estapé
    Minghui Zhao
    Bowen Qi
    Zongzhi Z. Liu
    Carolyn Kravitz
    Heather Hulme
    Nicole Strittmatter
    Francesc López-Giráldez
    Sampada Chande
    Alexandra E. Albert
    Mary-Ann Melnick
    Bomiao Hu
    Katerina Politi
    Veronica Chiang
    Nicola Colclough
    Richard J. A. Goodwin
    Darren Cross
    Paul Smith
    Don X. Nguyen
    Nature Communications, 13
  • [44] Mechanisms of resistance for osimertinib for patients with EGFR-mutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance
    Le, Xiuning
    Negrao, Marcelo Vailati
    Nilsson, Monique
    Robichaux, Jacqulyne
    Roarty, Emily
    Rinsurongkawong, Waree
    Glisson, Bonnie
    Zhang, Jianjun
    Heymach, John V.
    CANCER RESEARCH, 2018, 78 (13)
  • [45] Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment
    Uchibori, Ken
    Inase, Naohiko
    Nishio, Makoto
    Fujita, Naoya
    Katayama, Ryohei
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : 915 - 925
  • [46] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
  • [47] Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib
    Oztan, A.
    Fischer, S.
    Schrock, A. B.
    Erlich, R. L.
    Lovly, C. M.
    Stephens, P. J.
    Ross, J. S.
    Miller, V.
    Ali, S. M.
    Ou, S. -H. I.
    Raez, L. E.
    LUNG CANCER, 2017, 111 : 84 - 87
  • [48] Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report
    Lee, Po-Hsin
    Chang, Gee-Chen
    CLINICAL LUNG CANCER, 2021, 22 (04) : E536 - E541
  • [49] Acquired an EGFR Amplification in EGFR Exon 20 insertion Lung Adenocarcinoma Resistant to First Line Osimertinib Treatment
    Zhou, C.
    Chen, Z.
    Li, C.
    Wang, H.
    Lou, F.
    Cao, S.
    Liu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S595 - S595
  • [50] Impact of body surface area on efficacy and safety in patients with EGFR-mutant non-small cell lung cancer treated with osimertinib as a first-line treatment
    Tanaka, Saki
    Tamiya, Motohiro
    Nishiuma, Satoshi
    Nakamura, Sayaka
    Nozaki, Keisuke
    Watanabe, Naoko
    Itoh, Chisae
    Kadokawa, Yukio
    Takeda, Kenji
    Takahashi, Kozo
    Miyazaki, Akito
    Kawamura, Takahisa
    Kunimasa, Kei
    Inoue, Takako
    Nishino, Kazumi
    Takagi, Mari
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2024, 40
12345